
Sana Biotechnology (SANA) Stock
Clinical stage biotech company developing cell and gene therapies. Here's the price, business snapshot, and what's worth knowing about Sana Biotechnology in November 2026.
Sana Biotechnology Inc (SANA) is a clinical-stage biotechnology company developing platform technologies for cell and gene therapies. The firm pursues both in vivo and ex vivo approaches to engineer cells for treating a range of diseases, and its valuation—around $1.4 billion market cap—reflects investor expectations for future clinical progress. Key things an investor should know include the stage of the pipeline, upcoming trial readouts and regulatory milestones, partnerships and manufacturing scale-up, and the company’s cash runway and financing needs. Biotechnology investing is high risk and outcomes can be binary: positive clinical data can materially increase value, while setbacks can lead to significant share price declines. This summary is general educational information and not personalised investment advice; investors should conduct their own research and consider seeking professional financial guidance before acting.
Sana Biotechnology (SANA) Stock Forecast
Analyst price target, next 12 months
$9.42
+393.0% vs today's $1.91
Price range over the last 12 months
Close to its 12-month low
Analysts covering Sana Biotechnology have a consensus 12-month target of $9.42, above the current price of $1.91.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SANA Biotechnology's stock with a target price of $9.50, indicating strong potential growth.
Financial Health
SANA Biotechnology has a decent cash flow and book value, indicating stable financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Several clinical readouts and preclinical milestones could materially affect valuation, though outcomes are uncertain and performance can vary.
Platform Innovation Focus
Sana’s in vivo and ex vivo platforms aim to improve delivery and manufacturability, which may offer competitive advantages but are not guaranteed to produce approved therapies.
Partnerships and Scale
Collaborations and manufacturing scale-up can derisk development and expand reach, yet they require capital and regulatory alignment and may take time.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.